Recent Biosimilar Commercialization Developments
LexBlog IP
SEPTEMBER 28, 2023
to commercialize several of Abbott’s oncology, women’s health, and respiratory disease biosimilars for emerging markets in Latin America, Southeast Asia, the Middle East, and Africa. According to the press release, the first molecules subject to the agreement are expected to launch as early as 2025.
Let's personalize your content